Lack of immune recovery in HIV/Leishmania co-infection treated with human recombinant IL-2 [3]

AIDS

Volumn 21, Issue 9, 2007, Pages 1223-1225

  Bossolasco, Simona ^a   Nozza, Silvia ^a   Gaiera, Giovanni ^a   Bestetti, Arabella ^a   Lazzarin, Adriano ^a   Cinque, Paola ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; DIDANOSINE; MEGLUMINE ANTIMONATE; PENTAMIDINE; RECOMBINANT INTERLEUKIN 2; SAQUINAVIR; ZIDOVUDINE;

ADULT; CASE REPORT; CD4 LYMPHOCYTE COUNT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RELAPSE; TREATMENT DURATION; TREATMENT RESPONSE; VISCERAL LEISHMANIASIS;

ADULT; ANTIPROTOZOAL AGENTS; DNA, PROTOZOAN; FEMALE; HIV INFECTIONS; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; LEISHMANIASIS, VISCERAL; RECOMBINANT PROTEINS; TREATMENT FAILURE;

EID: 34248531794     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32810c8d27     Document Type: Letter

References (16)

1. Alvar J, Canavate C, Gutierrez-Solar B, Jimenez M, Laguna F, Lopez-Velez R, et al. Leishmania and human immunodeficiency virus co-infection: the first 10 years. Clin Microbiol Rev 1997; 10:298-319.
2. Del Giudice P, Mary-Krause M, Pradier C, Grabar S, Dellamonica P, Marty P, et al., French Hospital Database on HIV Clinical Epidemiologic Group. Impact of highly active antiretroviral therapy on the incidence of visceral leishmaniasis in a French cohort of patients infected with human immunodeficiency virus. J Infect Dis 2002; 186:1366-1370.
3. Mira JA, Corzo JE, Rivero A, Macias J, De Leon FL, Torre-Cisneros J, et al. Frequency of visceral leishmaniasis relapses in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. Am J Trop Med Hyg 2004; 70:298-301.
4. Wolday D, Berhe N, Akuffo H, Britton S. Leishmania-HIV interaction: immunopathogenic mechanisms. Parasitol Today 1999; 15:182-187.
5. Barreto-de-Souza V, Pacheco GJ, Silva AR, Castro-Faria-Neto HC, Bozza PT, Saraiva EM, et al. Increased Leishmania replication in HIV-1-infected macrophages is mediated by tat protein through cyclooxygenase-2 expression and prostaglandin E2 synthesis. J Infect Dis 2006; 194:846-854.
6. Carvalho EM, Badaro R, Reed SG, Jones TC, Johnson WD Jr. Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. J Clin Invest 1985; 76:2066-2069.
7. Cillari E, Liew FY, Lo Campo P, Milano S, Mansueto S, Salerno A. Suppression of IL-2 production by cryopreserved peripheral blood mononuclear cells from patients with active visceral leishmaniasis in Sicily. J Immunol 1988; 140:2721-2726.
8. Nigro L, Cacopardo B, Preiser W, Braner J, Cinatl J, Palermo F, et al. In vitro production of type 1 and type 2 cytokines by peripheral blood mononuclear cells from subjects coinfected with human immunodeficiency virus and Leishmania infantum. Am J Trop Med Hyg 1999; 60:142-145.
9. Mitsuyasu RT. The potential role of interleukin-2 in HIV. AIDS 2001; 15 (Suppl. 2):22-27.
10. Tambussi G, Ghezzi S, Nozza S, Vallanti G, Magenta L, Guffanti M, et al. Efficacy of low-dose intermittent subcutaneous interleukin (IL)-2 in antiviral drug-experienced human immunodeficiency virus-infected persons with detectable virus load: a controlled study of 3 IL-2 regimens with antiviral drug therapy. J Infect Dis 2001; 183:1476-1484.
11. Akuffo H, Kaplan G, Kiessling R, Teklemariam S, Dietz M, McElrath J, et al. Administration of recombinant interleukin-2 reduces the local parasite load of patients with disseminated cutaneous leishmaniasis. J Infect Dis 1990; 161:775-780.
12. Carvalho EM, Bacellar O, Brownell C, Regis T, Coffman RL, Reed SG. Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis. J Immunol 1994; 152:5949-5956.
13. Murray HW, Miralles GD, Stoeckle MY, McDermott DF. Role and effect of IL-2 in experimental visceral leishmaniasis. J Immunol 1993; 151:929-938.
14. Bossolasco S, Gaiera G, Olchini D, Gulletta M, Martello L, Bestetti A, Bossi L, et al. Real-time PCR assay for clinical management of human immunodeficiency virus-infected patients with visceral leishmaniasis. J Clin Microbiol 2003; 41:5080-5084.
15. Potestio M, D'Agostino P, Romano GC, Milano S, Ferlazzo V, Aquino A, et al. CD4+ CCR5+ and CD4+ CCR3+ lymphocyte subset and monocyte apoptosis in patients with acute visceral leishmaniasis. Immunology 2004; 113:260-268.
16. Mazingue C, Cottrez-Detoeuf F, Louis J, Kweider M, Auriault C, Capron A. In vitro and in vivo effects of interleukin 2 on the protozoan parasite Leishmania. Eur J Immunol 1989; 19:487-491.